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 22 
Introduction 23 
The management of multiple sclerosis (MS) has been a neurology success story for the past 25 24 
years. Advances in understanding of the disease mechanisms, and the dynamic nature of the 25 
disease, have brought around 12 disease-modifying therapies (DMTs) to market in many 26 
countries. 27 
However, treatment is hampered by adverse effects and by limited evidence of efficacy in 28 
more advanced “progressive” MS. Some patients do not receive DMTs for years after diagnosis, 29 
or are told medication can no longer help as their disability is worsening. The cost of DMTs is 30 
also a significant issue, especially in low and middle income countries.  31 
MS affects an estimated 2.5 million people worldwide, with a higher prevalence and 32 
incidence in the northern hemisphere.1 MS patients now have a longer life expectancy,2 3 in 33 
part because of earlier treatment. Accounting for co-morbidities such as age-related vascular 34 
disease will become increasingly important in patient management.4 35 
The Journal of Neurology Neurosurgery Psychiatry brought together a panel of experts on 36 
World MS Day 2017 to discuss the importance of time in MS – timing of initiation and 37 
withdrawal of disease-modifying treatment, time to consider contributory factors such as 38 
vascular disease, and the time and cost burden of MS. This paper, which originated in the 39 
round table discussion, reviews: 40 
 latest thinking in timing of disease management;  41 
 how treatment and prevention of vascular injury may buy additional time for 42 
people with MS;  43 
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 new data about the true economic and social burden of the disease, for people with 44 
MS and their carers. 45 
 46 
 47 
Timing of disease management: the case for starting disease modification treatment early 48 
MS damages the whole brain, and damage begins from the start of the disease. Every system in 49 
the brain - myelin, white matter, neurones, axons and blood vessels - is damaged by MS.5–7 50 
Brain atrophy, both in the cortex and the white matter, is progressive and accelerates over 51 
time.8 Evidence from MRI scans shows that even at the earliest stages of MS, people lose brain 52 
volume - and that it is lost at the same rate as someone with later stage disease.9 53 
Recent painstaking research using donated brain tissue found that people who die with MS 54 
have a neuron count 39% lower than people without MS,10 due, at least in part, to damage to 55 
fibre tracts and subsequent retrograde/anterograde neuronal degeneration.11 This loss is 56 
strongly associated with the thickness of the cortical and deep grey matter,12 13 which suggests 57 
cortical volume measures using MRI that are predictive of clinical outcome indeed reflect 58 
neuronal loss.14 59 
While repair of brain plaques can be detected in the early stages of MS, the regenerative 60 
potential of the brain is limited and becomes less effective with age.15–17 Results of trials 61 
attempting to induce regeneration have so far not been very promising.18 62 
 All this suggests that swift action to prevent or slow damage to the brain is crucial. 63 
Clinicians must act before the disease causes irreparable damage to the brain, and before the 64 
brain’s limited mechanisms for repair are damaged. There is increasing consensus about the 65 
importance of early intervention to maximise lifelong brain health.19 66 
So, when should treatment start and what criteria should guide a clinician’s decision as to 67 
when to offer disease-modifying treatment? Clinicians often think of MS progression in terms 68 
of walking ability, and judge the progress of MS by performance on tests such as the timed 25-69 
foot walk. However, for people with MS, cognitive health is of major importance, and is 70 
impaired before walking ability. Cognitive deficit, not walking ability, has the biggest impact on 71 
the employment status of people with MS.20 72 
Cognition decreases over time with MS, right from the outset.21 Even people with 73 
radiographically-isolated syndrome suggestive of MS may have hidden cognitive deficits.22 On 74 
the other hand, people with MS and normal cognitive function may also have compromised 75 
brain functioning 23 putting them at impending risk of collapse. While early structural damage 76 
might in many patients preserve overall network efficiency, its continuous accumulation during 77 
the course of disease leads to an inevitable decrease in such efficiency (increased or additional 78 
recruitment of brain areas and/or altered connectivity between regions).24 Importantly, 79 
cognitive impairment might not be apparent until brain network efficiency reaches a certain 80 
threshold, which seems to be different from individual to individual according to, among other 81 
factors,  premorbid cognitive reserve.25 82 
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Indeed, evidence shows that children who go on to develop MS in adulthood show evidence 83 
of poorer school performance, suggesting that the disease could be affecting cognition 5 to 10 84 
years before any clinical manifestation can be seen.26 85 
If cognitive decline starts so early, we need to begin treating MS with disease-modifying 86 
drugs as soon as we are aware of it. 87 
The best long-term evidence that we have, from follow-up studies on participants in early 88 
trials of interferon beta, showed a clear improvement in mortality for patients who started the 89 
drug 1 or 2 years earlier.27 We can also see an impact on disability. Long-term follow up of 90 
early trials of natalizumab showed that, even after five years, patients who were in the initial 91 
treatment group had a lower Expanded Disability Status Scale (EDSS) score than those who 92 
were initially treated with placebo and started active treatment 2 years later.28 93 
The impact of treatment may decrease as the disease unfolds in line with the natural 94 
history of MS, where we can see that the impact of relapses on disability progression is higher 95 
in the earlier stages of the disease.29 96 
A recent positive trial of siponimod in secondary progressive MS further suggested that, 97 
even in the latter phases, disease duration is a key factor in determining the impact that drugs 98 
can make. The study found the effect of siponimod in delaying confirmed disability progression 99 
decreased as disease duration increased, such that the only patient group with significant 100 
decrease in confirmed disability progression on drug treatment were those diagnosed within 10 101 
years.30 102 
 103 
Timing of disease management: The case for continued treatment of progressive disease 104 
One inference of the ‘treat early’ concept is that, beyond a certain point of disability, usually 105 
expressed as around stage 3 or 4 on the EDSS, the disease can no longer be modified 31 and 106 
DMT is therefore without merit.32 That inference has more recently been challenged following 107 
review of past trial evidence 33,34 and new data 35,36 indicating that even people at a more 108 
advanced stage of MS may benefit from DMT.  109 
The difference in responsiveness to DMT between upper limb (and cognitive problems) and 110 
lower limb (and, for example, bladder) dysfunction suggest a degree of length-dependency of 111 
nerve damage.37–39 Evidence suggests nerve fibre tracts to the lower spine are more likely to be 112 
damaged in more places than shorter nerve fibre tracts.40,41 Moreover, more than 50% of 113 
cortico-spinal tract fibres have already terminated once they approach the neck portion of the 114 
spinal cord, providing a naturally higher redundancy of tracts supplying the arms and hands, 115 
and other important for functions such as swallowing and speech.42–44 116 
We are now seeing increasing evidence that disease modification is possible at later stages 117 
of disease, even after walking function has been lost.45–48 Patients value upper limb function 118 
and are keen to be included in studies after the loss of walking ability - a recent survey showed 119 
95% of patients disagree with the idea that wheelchair-users should be excluded from MS 120 
studies.49 121 
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A study published last year showed that the anti-CD20 monoclonal antibody ocrelizumab 122 
can slow deterioration in people with primary progressive MS, with a 25% reduction in EDSS-123 
measured disability progression at 12 and 24 weeks.50 Looking at upper limb function, the 124 
study reported a 44% difference in upper limb function between treated and non-treated 125 
patients, in line with the length-dependency hypothesis.51 126 
Ocrelizumab is the first drug to have been licensed for primary progressive MS. A phase 127 
three trial of fingolimod (INFORMS) failed to show an overall impact of the drug on disability in 128 
progressive MS.52 However, case studies from the trial suggest that some patients do indeed 129 
benefit from the treatment. One patient enrolled in the INFORMS trial had a catastrophic 130 
deterioration four months after discontinuing fingolimod as a result of the trial termination, 131 
which was due to the negative outcome of the cohort on the primary endpoint (EDSS). She 132 
experienced a step change in disability level from EDSS 6.5 to 8 and hand function in particular. 133 
Subsequent treatment with off-label cladribine helped her regain some of the lost function.53 134 
Evidence from MRI and other studies clearly show that the concept of progressive MS54 as a 135 
“non-inflammatory stage” of MS is wrong.55 Earlier pathology studies demonstrated significant 136 
association between inflammation and axonal damage, regardless of whether the patient had 137 
progressive or relapsing MS.56–58 138 
While anti-inflammatory disease modifying treatment should be started as early as possible, it 139 
should not necessarily be given up when patients develop progressive MS. To demonstrate benefit, 140 
trials will need to include outcomes that are sensitive to functions that can be protected or 141 
recovered at an advanced stage of the disease, including upper limb function, dexterity, 142 
swallowing and speech.59 High quality surrogate indices, such as the impact of new compounds on MRI 143 
indices of brain or spinal cord volume of are useful in phase II trials to estimate likely clinical benefit.60–62 144 
 145 
It is important to bear in mind that clinical and surrogate indices should reflect changes 146 
that are meaningful for people with MS. The concept of “treat early and never stop” should be 147 
mindful of the adverse effects associated with DMTs, - predominantly lowered immune 148 
function and increased susceptibility to infection and neoplasms.1 149 
For a fully-informed treatment choice, people with MS need time for comprehensive 150 
education about all aspects of their DMT management. Early treatment with a highly effective 151 
DMT may be beneficial in terms of disease control but at the trade-off of increased risk of 152 
adverse effects. For example, alemtuzumab leads to no evidence of disease activity over years 153 
in more than 60% of patients and a nearly normalised brain atrophy rate in many,63 but the risk 154 
of secondary autoimmunity can reach nearly 50%.64 155 
The long-term value of such an intervention, compared to an escalation strategy, remains 156 
to be confirmed. The number of effective compounds has increased significantly over recent 157 
years, and high efficacy is not now always synonymous with high risk.65–67 Patients and 158 
physicians should keep an open mind, be prepared to monitor efficacy and adverse effects and 159 
switch DMT as required. 160 
Early detection and diagnosis may allow for suppression of inflammation to a degree that could 161 
prevent or stop the development of neurodegeneration. For example, data from the alemtuzumab 162 
programme indicate that such high efficacy with long term remission can be achieved in some patients.68 69 163 
 164 
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Ageing with MS: time to intervene in vascular disease prevention 165 
MS is a chronic disease, in the majority of cases, initially characterised by acute bouts of 166 
inflammation that translate into transient neurological dysfunction. At some point - often 167 
around age 40 to 50 - the clinical phenotype may transition to a progressive phase70–73 during 168 
which further mechanisms, over and above focal inflammatory demyelination, contribute to 169 
disease evolution.74 75 These include mitochondrial dysfunction,76 hypoxia,77 iron 170 
accumulation78 and fibrogen deposition,79 and contribute to amplify neurodegeneration,76 80 81 171 
particularly in late-stage disease or older patients, where inflammation is less prominent58 82 172 
and neuronal loss seems to be relatively independent from demyelation.10 173 
Older age seems to influence the clinical phenotype, patients with progression from disease 174 
onset being typically older than those with a relapsing remitting onset. Age influences not only 175 
the onset and transition into clinical progressive MS but also the pathological hallmarks and 176 
mechanisms which feature progressive disease, despite the initial clinical phenotype.83 177 
Vascular disease is also an age-related phenomenon, with an accumulation of atheroma in 178 
blood vessels from an early age which can lead later in life to heart disease (around the age 50s 179 
and 60s) and brain damage (after age 60).84 Vascular risk factors, such as hypertension, 180 
diabetes and dyslipidemia also contribute to the accumulation of vessel atheroma and have 181 
been linked to changes in the brain, including brain volume loss, white matter lesions and small 182 
haemorrhages visible in MRI scans of people with vascular risk factors but no MS. In turn, these 183 
changes correlate with cognitive dysfunction and walking impairment.85–87 184 
A key and unresolved question is whether people with MS have an increased risk of 185 
vascular disease such as stroke, compared to people without MS.88–91 Epidemiological data 186 
suggests that cardiovascular disease is an important cause of death in MS,92 and that people 187 
with MS have a small increase in risk of stroke.93 94 However, this finding should be treated 188 
with caution, as it could be due to surveillance bias or the impact of immobilisation that 189 
features in late stage MS.95 Morphological changes in brain blood vessels, such as vessel wall 190 
thickening, have been described in people with MS.96–98 As in other inflammatory disorders 191 
such as rheumatic diseases,99 cerebral vessels exposed to MS chronic inflammation could be 192 
prone to atheroma and atherosclerosis. This hypothesis is to be investigated. 193 
Even if patients with MS don’t have a greater risk of vascular disease than the general 194 
population, 17% of all MS patients have hypertension and 8% have hyperlipidaemia at the time 195 
of diagnosis,100 with older MS patients having a higher prevalence of these vascular risk 196 
factors.101 197 
Vascular risk factors and disease are associated with worse outcomes in people with MS. It 198 
is well known that smoking reduces time to secondary progression, but perhaps less well 199 
known that the presence of any vascular risk factor is linked to reduced time to walking 200 
disability.102 103 The exact mechanisms underlying the effect of vascular risk factors in disability are 201 
unclear but it is possible that blood vessels already exposed to chronic inflammation are put under 202 
additional pressure through vascular risk factors.104 203 
It’s not difficult to see why this might be. Cerebral blood vessels provide oxygen and 204 
nutrients to nerve cells, and are key intermediaries between nerve cells and the immune 205 
system. Damaged blood vessels contribute to nerve hypoperfusion and hypoxia and there is 206 
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evidence of brain hypoperfusion in MS. Maps of cerebral blood flow show that areas of low 207 
blood perfusion co-localise with both T1 and T2 MS lesions105 and MS lesions tend to 208 
accumulate in ‘watershed’ areas (areas between two vascular territories, where there is 209 
hypoperfusion).106 210 
MS and small vessel cerebrovascular disease may be difficult to distinguish.107 108 More 211 
specific markers are required to enable clinicians to distinguish between MS progression that 212 
might be treated by DMTs and cerebral damage that is a result of cerebrovascular disease. 213 
While clinical studies of vascular risk factors in MS are hard to envisage, large-scale 214 
epidemiological studies, drawing on big data from patient databases, may provide some 215 
answers. This might help to untangle the ways in which each vascular risk factor has an impact 216 
on the progression of MS. 217 
Although the association between vascular disease and MS is not fully understood, it is 218 
possible that vascular risk factors109 110 or vascular pathology can cause additional damage to 219 
the brains of people with MS, over and above that caused by MS alone.111–113 Though this 220 
needs further confirmation, information about patients’ vascular status should be incorporated 221 
into clinical trials. MS is a heterogeneous disease and at the individual level, time to reach the 222 
secondary progressive phase is variable. The role of age-related vascular disease on MS 223 
progression onset and phenotypic presentation has still to be investigated. If time matters in 224 
protecting the brain from inflammation-related damage in relapsing remitting MS, it also 225 
matters in protecting the brain from additional damage from vascular disease. 226 
We know that patients who stop smoking sooner have better outcomes.114 It’s time to take 227 
other vascular risk factors seriously. Clinicians should talk to patients about vascular risk and 228 
encourage them to take preventive action in the form of smoking cessation, diet and exercise. 229 
Vascular risk factors or morbidities such as hypertension should be assessed and treated, 230 
before they begin to add to the burden of brain damage. Proper, timely interventions in 231 
patients’ vascular health may help buy additional time to treat MS. Integrated care requires 232 
consideration of the body outside of the nervous system, as well as the nervous system and 233 
brain. 234 
 235 
Costs and burdens of MS 236 
Part of the struggle to ensure everyone who needs appropriate treatment for MS can access it 237 
stems from concerns around costs. Uncovering the true benefits of MS treatment could help 238 
the MS community to make the case for funding of treatment. 239 
Because MS is a disease in which disability accrues slowly, yet studies of treatment are 240 
often of only 2 to 3 years’ duration, it can be challenging to show the full extent of the 241 
benefits. Health economists look for data that demonstrates quality of life gains for the 242 
individual affected, yet this may not capture the full extent of the economic benefits of 243 
treatment - not only for the health service and the person being treated, but for their carers as 244 
well. 245 
MS is an expensive disease, and the costs rise sharply in line with increased disability and 246 
plummeting quality of life. Two new studies have gathered more data about the burdens and 247 
costs of MS in Europe. The aim is to demonstrate evidence of the impact of an effect of 248 
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treatment on disease progression that will prevent or delay patients reaching a disease state 249 
with higher costs and lower quality of life. 250 
The first of these studies is the largest study ever performed of MS disease burden and 251 
treatment.115 The observational, cross-sectional study included data from 16,808 patients from 252 
16 countries across Europe. Patients were contacted by national MS societies and provided 253 
data collected by questionnaires, either online or in printed form. The study collected 254 
information on patient characteristics, disease type, use of resources and loss of resource 255 
(including work capacity) over the previous 3-month period. The EDSS was used to stratify 256 
patients by disease level. 257 
Results were highly heterogenous between countries, including sample size, average age 258 
and disability level. The results also reflected differences in healthcare systems and informal 259 
care traditions in different countries. However, the findings confirmed the relationship 260 
between costs and disability, finding that costs increase on average 5-fold between mild and 261 
severe MS. 262 
One clear difference was in the proportion of patients using DMTs. Spain, France and 263 
Portugal had the highest proportion of patients taking these medications. These results may 264 
have reflected the average level of disability and disease type in the cohort of each country. 265 
The UK cohort, for example, had a higher proportion of patients with progressive disease, 266 
which may explain the relatively low proportion using DMTs. Overall, the study found, as might 267 
be expected, that DMTs are more frequently used at lower EDSS scores, and very little used in 268 
people with higher EDSS scores. Fatigue and cognitive difficulties have a major effect on 269 
patients’ productivity. The study results suggest that renewed focus on fatigue and cognitive 270 
function is critical. They are not incidental symptoms, but a fundamental manifestation of MS 271 
which should be actively managed. 272 
The study found that many patients of working age were not working, and that this reached 273 
50% of the cohort at EDSS score of 3.5. The implication is that MS affects employment status 274 
before physical disability sets in. Some 95% of patients complained of fatigue and cognitive 275 
difficulties. Given the difficulty of objectively assessing one’s own cognitive function, this may 276 
be an underestimate. 277 
The study findings on healthcare resource use provide an insight into different healthcare 278 
models. The proportion of patients who reported having seen a neurologist in the past three 279 
months varied considerably, from 81% in Germany to 25% in the UK. This correlated inversely 280 
with use of specialist nurses - where patients frequently saw neurologists, they were less likely 281 
to have seen an MS nurse, or a physiotherapist. 282 
The study showed wide variation in the models of care. While data from a ‘snapshot’ cross-283 
sectional study is difficult to evaluate, some countries have done work to evaluate the cost 284 
effectiveness of different models of care. The results may help the MS community to develop 285 
an optimum model of care, which might cover access to DMTs, early treatment, high quality 286 
services and the optimal balance between different health care professionals. The 287 
heterogeneity of findings suggests that healthcare consumption is currently more influenced by 288 
systems and tradition than by the disease itself. 289 
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Some countries had a very high percentage of informal care, possibly relating to the 290 
traditional care models in that country. Others had less use of informal care, which might 291 
relate to more developed formal care services, or more access to formal care services. For 292 
most countries, use of informal care increased with increasing disability scores. In some 293 
countries, informal carers were providing 150 hours a month of care to patients - the 294 
equivalent of full time employment.115 295 
Further insight into the experience of patients and carers came from the Impress study, 296 
which included an online survey of 1,152 people with MS and 265 carers, from 19 countries.116 297 
Most patients had relapsing MS, although some were unsure, reflecting the confusion 298 
around classification of MS. Most patients were treated with DMTs (around 80% of those with 299 
relapsing MS and, surprisingly, almost all those with primary progressive MS). However, only a 300 
fraction of these people were taking oral DMTs. Patients who had received prompt treatment - 301 
within 12 months of first symptoms plus confirmatory MRI evidence - were more likely to be 302 
taking oral DMTs, and reported fewer hospital admissions, compared to those whose treatment 303 
was delayed beyond 12 months. 304 
The study revealed a ‘care gap’ between the amount of care people received and the 305 
amount they believed they needed. Questions about quality of life and disability score showed 306 
that the EuroQol Five Dimensions (EQ5D) questionnaire may not necessarily capture what 307 
matters most to patients - notably fatigue, weakness, balance and dizziness. Patients say these 308 
things are important to them, yet they are not captured by generalised quality of life 309 
questions. Patients tend to rate themselves relatively highly on quality of life, even when their 310 
disability score suggests they are not doing so well. 311 
The study found that patients rate access to information very highly, and tend to look 312 
online for information, primarily from MS-specific organisations or charities. Patients felt they 313 
needed good quality information to participate in shared decision making. While they valued 314 
the opinion of the clinician, they also wanted the opportunity to discuss options with them, 315 
and 67% said they wanted to be active in the decision-making process and management of 316 
their care.  317 
The figures about informal care backed up the findings of the bigger study, showing a huge 318 
impact on carers’ economic activity, with an annual figure of €31,653 loss of productivity. 319 
Despite this, carers tended not to rate their caring duties as burdensome. 320 
Taken together, these studies demonstrate that the greatest costs of MS are not the drugs 321 
to treat the disease, but the cost of informal care and loss of productivity, both of patients and 322 
their informal carers. Bringing new evidence about these costs into health technology 323 
assessments would be a step forward in recognising the contributions of informal care, and the 324 
costs incurred. 325 
 326 
Early evidence for economic analysis 327 
Despite the advances made in disease modifying therapy for patients with relapsing MS over 328 
the past 25 years, patients with progressive MS who make up over 60% of the MS population, 329 
do not currently have access to a therapy licensed for their treatment.117 330 
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This is in part a reflection of our limited understanding of the mechanisms underpinning 331 
progression, in addition to of the complex hurdles that therapies must overcome to gain not 332 
only a licence for an indication, but to be judged both cost-effective and affordable by those 333 
meeting the costs of therapy. 334 
Based on the indication for which the licence is granted - which with MS is often restricted 335 
by disease severity or stage - individual countries will determine whether to reimburse the 336 
drug though their healthcare system, using health technology assessment. This process, which 337 
usually takes at least 12 months, will consider cost effectiveness and value for money and will 338 
look for added therapeutic value. 339 
The two further decision-makers, after the regulatory authorities and the payment 340 
authorities have had their say, are the prescriber - who considers the likely performance of the 341 
drug compared to other therapies for the individual patient - and potentially the patient, who 342 
may have to decide whether he or she is willing or able to pay for the treatment (if they pay 343 
directly for medical care) and whether to adhere to treatment.118 344 
How can this process be speeded up so that effective therapies can get to the patients who 345 
benefit from them more quickly? 346 
Phase two trials can be extended to look at disability end points and provide longer-term 347 
data which may be helpful for health technology assessment. Phase three trials tend to include 348 
disability end points and the sustained effect of therapies on disability. However, while these 349 
trials can look at impairments - what level of disability scores people have, and how these 350 
change over time - they are less good at considering how impairments affect the patient’s 351 
activities and role in society. This is complicated, because two patients with similar 352 
impairments may feel they have different levels of disability, perhaps based on external factors 353 
such as their social support and expectations. This makes it very difficult to truly measure the 354 
impact of disability.119 355 
Tools that assess the effects of limitations on activities and participation in society do exist, 356 
but are not specific enough to be sure that the limitation is caused by MS. A combination of 357 
MS-specific disability measures and these wider tools might give us a better picture, but this 358 
would be excessively cumbersome for use in routine assessments. Most endpoints currently 359 
measured look at clinical signs, not functioning. Global functional tools are variable and have a 360 
bias towards diagnosis of depression. There is a need to develop better tools to measure 361 
disability and its effect on patients’ functioning and societal role, if we are to provide good 362 
evidence of the true burden of MS on society, and the related cost-benefit of therapies. 363 
Meantime, we need to find a way to get therapies which are licensed for one indication and 364 
now off-patent (such as statins) but may have useful activity for MS, into the health technology 365 
appraisal system. At present, there is no incentive for a manufacturer to fund an expensive 366 
clinical trial of statins for treatment of MS, and most health technology assessment systems 367 
will only assess therapies licensed for the indication being proposed.120 368 
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Conclusion 369 
New insights about the timing and duration of MS therapies, and about the importance of co-370 
morbidities, present us with great opportunities to make significant improvements to the lives of 371 
people with MS.  372 
While the research we outline highlights a significant level of unmet need in a relatively young and 373 
economically active population, this information can be used to press for more widespread 374 
adoption of the principles of early effective treatment and long term follow-up to keep disease 375 
activity in check. This adoption must come now not just from clinicians and patients, but also from 376 
drug regulators and payers (insurers and tax funded healthcare).  377 
More widespread adoption of these principles could help us to build on the successes of the 378 
therapeutic advances we have seen over the past 25 years, ensuring that everyone who can 379 
benefit from treatment does so, and that no patients are left behind. We already know that “time 380 
matters” when treating MS. Now it’s time to take that message to those planning services, 381 
regulating healthcare technologies and setting the healthcare agenda. 382 
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